person · Reporting owner

Aghazadeh Behzad

Disclosed activity across 5 companies

Tapewire entity: 28272
SEC CIK: 0001701815

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Scribe Therapeutics, Inc.SCTX · Entity 5494	Director · 10% owner · See Remarks	July 24, 2026	July 29, 2026
Whitehawk Therapeutics, Inc.WHWK · Entity 6074	Director · 10% owner · See remarks	June 12, 2026	June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Scribe Therapeutics, Inc.

Report date July 24, 2026 · Filed July 29, 2026

Jointly reported with Avoro Capital Advisors LLC, Avoro Ventures LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	3,030,983	Reported balance After 2026-07-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-07-24 · Purchase · Acquired 2,333,333 · Balance 3,030,983 F1: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds"). F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	3,080,983	Reported balance After 2026-07-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-07-24 · Purchase · Acquired 50,000 · Balance 3,080,983 F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnotes	3,088,888	Reported balance After 2026-07-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-07-28 · Purchase · Acquired 7,905 · Balance 3,088,888 F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F3: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund. F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").

F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.

F3: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.

F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.

F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).

F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.

Whitehawk Therapeutics, Inc.

Report date June 12, 2026 · Filed June 15, 2026

Jointly reported with Avoro Capital Advisors LLC, Avoro Ventures LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12	Direct	38,040	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. F2: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

F2: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

F3: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CymaBay Therapeutics, Inc.

Report date September 12, 2023 · Filed September 14, 2023

Jointly reported with Avoro Capital Advisors LLC

Section 16 reporting ended · disclosed 2023-09-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Put Option (obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2023-10-20	IndirectSee footnotes	1,500	Reported balance After 2023-09-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-12 · Sale · Disposed 1,500 · Balance 1,500 F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Put Option (obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2023-10-20	IndirectSee footnotes	300	Reported balance After 2023-09-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-12 · Sale · Disposed 300 · Balance 300 F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Put Option (obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2023-10-20	IndirectSee footnotes	250	Reported balance After 2023-09-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-13 · Sale · Disposed 250 · Balance 250 F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Put Option (obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2023-10-20	IndirectSee footnotes	950	Reported balance After 2023-09-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-13 · Sale · Disposed 950 · Balance 950 F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Pre-funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnotes	583,771	Reported balance After 2023-09-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-12 · Purchase · Acquired 583,771 · Balance 583,771 F3: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 14, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein and all other warrants beneficially owned by the Reporting Persons contain an exercise limitation prohibiting the holder from exercising the Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, none of the warrants beneficially owned by the Reporting Persons are presently exercisable. F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

F3: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 14, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein and all other warrants beneficially owned by the Reporting Persons contain an exercise limitation prohibiting the holder from exercising the Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the "Blocker"). Due to the Blocker, none of the warrants beneficially owned by the Reporting Persons are presently exercisable.

IMMUNOMEDICS INC

Report date October 23, 2020 · Filed October 23, 2020

Jointly reported with Avoro Capital Advisors LLC

Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-10-23 · Disposition to issuer · Disposed 13,516 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2020-10-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-10-23 · Disposition to issuer · Disposed 26,250,000 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. F2: Such securities were held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons was the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-23 · Disposition to issuer · Disposed 202,614 · Balance 0 F4: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-23 · Disposition to issuer · Disposed 103,718 · Balance 0 F5: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

F2: Such securities were held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons was the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

F4: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F5: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Mirati Therapeutics, Inc.

Report date July 23, 2019 · Filed July 25, 2019

Jointly reported with Avoro Capital Advisors LLC

Section 16 reporting ended · disclosed 2019-07-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnotes	3,800,000	Reported balance After 2019-07-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-07-23 · Sale · Disposed 62,500 · Balance 3,800,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.1321 to $104.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F2: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.1321 to $104.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2018 Filed Jun 19, 2018 16:05 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	PurchaseCommon Stock, $0.01 par value per share	200,000	$23.39	$4,678,000.00	Disclosure SEC source: 0000902664-18-002624 · p18-1346form4.xml · nonDerivative · entry 1 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 17,714,461 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.32 to $23.4998 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
June 11, 2018 Filed Jun 12, 2018 13:57 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseWarrant (right to buy) · Derivative	63,235	$38.85 Strike: $0.00	$2,456,616.52	Disclosure SEC source: 0000902664-18-002549 · p18-1318form4.xml · derivative · entry 2 venBio Select Advisor LLC · CIK 0001633313 · 10% owner Aghazadeh Behzad · CIK 0001701815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 63,235 Underlying: Common Stock · 63,235 shares Expires not disclosed F3 · derivative.expiration_date: These warrants can be exercised at any time. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
June 11, 2018 Filed Jun 12, 2018 13:57 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock, $0.001 par value per share ("Common Stock")	400,000	$38.85	$15,540,000.00	Disclosure SEC source: 0000902664-18-002549 · p18-1318form4.xml · nonDerivative · entry 1 venBio Select Advisor LLC · CIK 0001633313 · 10% owner Aghazadeh Behzad · CIK 0001701815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,798,101 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
April 02, 2018 Filed Sep 18, 2018 17:18 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	6,497	$0.00 Strike: $14.29	$0.00	Disclosure SEC source: 0001171843-18-006617 · ownership.xml · derivative · entry 3 Aghazadeh Behzad · CIK 0001701815 · Director · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock, par value $0.01 per share · 6,497 shares Expires 2025-04-02 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F5 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Dr. Aghazadeh's continued service as a director of the Issuer. Read SEC document
April 02, 2018 Filed Sep 18, 2018 17:18 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCommon Stock, $0.01 par value per share	3,849	$0.00	$0.00	Disclosure SEC source: 0001171843-18-006617 · ownership.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Behzad Aghazadeh's ("Dr. Aghazadeh") continued service as a director of the Issuer. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Behzad Aghazadeh's ("Dr. Aghazadeh") continued service as a director of the Issuer. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherPut Option (obligation to buy) · Derivative	1,250	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 7 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: Not disclosed Underlying: Common Stock · 125,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherCall Option (right to buy) · Derivative	1,250	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 6 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: Not disclosed Underlying: Common Stock · 125,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherPut Option (obligation to buy) · Derivative	2,500	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 5 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: Not disclosed Underlying: Common Stock · 250,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherCall Option (right to buy) · Derivative	2,500	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 4 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: Not disclosed Underlying: Common Stock · 250,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherPut Option (obligation to buy) · Derivative	5,000	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 3 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherCall Option (right to buy) · Derivative	5,000	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · derivative · entry 2 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: Not disclosed Underlying: Common Stock · 500,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
February 16, 2018 Filed Feb 16, 2018 17:39 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	OtherCommon Stock, $0.01 par value per share (the "Common Stock")	875,000	$7.00	$6,125,000.00	Disclosure SEC source: 0000902664-18-001218 · p18-0648form4.xml · nonDerivative · entry 1 venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 16,939,461 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
November 16, 2017 Filed Nov 16, 2017 14:44 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherWarrant (right to buy) · Derivative	37,500	$0.00 Strike: $7.86	$0.00	Disclosure SEC source: 0000902664-17-004377 · p17-2249form4.xml · derivative · entry 3 venBio Select Advisor LLC · CIK 0001633313 · 10% owner Aghazadeh Behzad · CIK 0001701815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2017-11-21 F3 · derivative.exercise_date: These warrants can be exercised at any time before the expiration date. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
November 16, 2017 Filed Nov 16, 2017 14:44 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	OtherCommon Stock	37,500	$7.86	$294,750.00	Disclosure SEC source: 0000902664-17-004377 · p17-2249form4.xml · nonDerivative · entry 2 venBio Select Advisor LLC · CIK 0001633313 · 10% owner Aghazadeh Behzad · CIK 0001701815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,398,101 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
November 16, 2017 Filed Nov 16, 2017 14:44 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	PurchaseCommon Stock, $0.001 par value per share (the "Common Stock"	650,000	$13.00	$8,450,000.00	Disclosure SEC source: 0000902664-17-004377 · p17-2249form4.xml · nonDerivative · entry 1 venBio Select Advisor LLC · CIK 0001633313 · 10% owner Aghazadeh Behzad · CIK 0001701815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,360,601 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
November 15, 2017 Filed Nov 15, 2017 17:48 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	PurchaseCommon Stock	175,000	$10.97	$1,919,750.00	Disclosure SEC source: 0000902664-17-004365 · p17-2245form4.xml · nonDerivative · entry 2 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 16,064,461 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.6584 to $11.3049 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
November 14, 2017 Filed Nov 15, 2017 17:48 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	PurchaseCommon Stock, $0.01 par value per share (the "Common Stock")	1,150,000	$10.39	$11,948,500.00	Disclosure SEC source: 0000902664-17-004365 · p17-2245form4.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 15,889,461 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.2 to $10.8403 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 24, 2017 Filed Oct 12, 2017 16:07 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	ConversionSeries A-1 Convertible Preferred Stock · Derivative	184,000	Not disclosed Strike: $5.41	Not disclosed	Disclosure SEC source: 0000902664-17-003965 · p17-2058form4.xml · derivative · entry 2 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,251,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F3 · price: Pursuant to the terms of the Certificate of Designation of the Series A-1 Convertible Preferred Stock, the shares of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock without any action by the Reporting Persons on August 24, 2017. These shares of Series A-1 Convertible Preferred Stock had no expiration date. F3 · derivative.exercise_date: Pursuant to the terms of the Certificate of Designation of the Series A-1 Convertible Preferred Stock, the shares of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock without any action by the Reporting Persons on August 24, 2017. These shares of Series A-1 Convertible Preferred Stock had no expiration date. F3 · derivative.expiration_date: Pursuant to the terms of the Certificate of Designation of the Series A-1 Convertible Preferred Stock, the shares of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock without any action by the Reporting Persons on August 24, 2017. These shares of Series A-1 Convertible Preferred Stock had no expiration date. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 24, 2017 Filed Oct 12, 2017 16:07 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	ConversionCommon Stock, $0.01 par value per share (the "Common Stock")	4,251,386	Not disclosed	Not disclosed	Disclosure SEC source: 0000902664-17-003965 · p17-2058form4.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 14,739,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Pursuant to the terms of the Certificate of Designation of the Series A-1 Convertible Preferred Stock, the shares of Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock without any action by the Reporting Persons on August 24, 2017. These shares of Series A-1 Convertible Preferred Stock had no expiration date. F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 23, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	SalePut Option (obligation to buy) · Derivative	1,250	$0.76 Strike: $7.00	$950.63	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 6 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,750 Underlying: Common Stock · 125,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 23, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCall Option (right to buy) · Derivative	1,250	$3.24 Strike: $7.00	$4,046.00	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 5 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,750 Underlying: Common Stock · 125,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	SalePut Option (obligation to buy) · Derivative	2,500	$0.73 Strike: $7.00	$1,822.75	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 4 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,500 Underlying: Common Stock · 250,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 22, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCall Option (right to buy) · Derivative	2,500	$3.20 Strike: $7.00	$8,007.75	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 3 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,500 Underlying: Common Stock · 250,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 21, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	SalePut Option (obligation to buy) · Derivative	5,000	$0.77 Strike: $7.00	$3,849.50	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 2 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,000 Underlying: Common Stock · 500,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
August 21, 2017 Filed Aug 23, 2017 16:55 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCall Option (right to buy) · Derivative	5,000	$2.84 Strike: $7.00	$14,211.50	Disclosure SEC source: 0000902664-17-003421 · p17-1761form4.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.01 per share ("Common Stock") · 500,000 shares Expires 2018-02-16 F1 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document
July 03, 2017 Filed Jul 6, 2017 18:02 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	22,500	$0.00 Strike: $9.02	$0.00	Disclosure SEC source: 0001104659-17-043898 · a4.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · See Remarks venBio Select Advisor LLC · CIK 0001633313 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-07-03 Read SEC document
May 04, 2017 Filed May 8, 2017 18:56 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantSeries A-1 Convertible Preferred Stock, par value $0.01 · Derivative	184,000	$125.00 Strike: $5.41	$23,000,000.00	Disclosure SEC source: 0000902664-17-002229 · p17-1181form4.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · See Remarrks venBio Select Advisor LLC · CIK 0001633313 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 184,000 Underlying: Common Stock, par value $0.01 per share ("Common Stock") · 4,251,386 shares Expires not disclosed F1 · security: These shares of Series A-1 Convertible Preferred Stock are automatically convertible into shares of common stock, par value $0.01 per share (the "Common Stock") upon approval by the Issuer's stockholders to increase the number of the Issuer's authorized shares of Common Stock to enable conversion of all outstanding shares of Series A-1 Convertible Preferred Stock. As of the date hereof, approval by stockholders of the Issuer has not been obtained and, accordingly, the Series A-1 Convertible Preferred Stock is not currently convertible. F1 · derivative.exercise_date: These shares of Series A-1 Convertible Preferred Stock are automatically convertible into shares of common stock, par value $0.01 per share (the "Common Stock") upon approval by the Issuer's stockholders to increase the number of the Issuer's authorized shares of Common Stock to enable conversion of all outstanding shares of Series A-1 Convertible Preferred Stock. As of the date hereof, approval by stockholders of the Issuer has not been obtained and, accordingly, the Series A-1 Convertible Preferred Stock is not currently convertible. F1 · derivative.expiration_date: These shares of Series A-1 Convertible Preferred Stock are automatically convertible into shares of common stock, par value $0.01 per share (the "Common Stock") upon approval by the Issuer's stockholders to increase the number of the Issuer's authorized shares of Common Stock to enable conversion of all outstanding shares of Series A-1 Convertible Preferred Stock. As of the date hereof, approval by stockholders of the Issuer has not been obtained and, accordingly, the Series A-1 Convertible Preferred Stock is not currently convertible. F2 · ownership.nature: The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.